212 related articles for article (PubMed ID: 32304470)
1. Update on group A streptococcal vaccine development.
Dale JB; Walker MJ
Curr Opin Infect Dis; 2020 Jun; 33(3):244-250. PubMed ID: 32304470
[TBL] [Abstract][Full Text] [Related]
2. Group A streptococcal vaccines: facts versus fantasy.
Steer AC; Batzloff MR; Mulholland K; Carapetis JR
Curr Opin Infect Dis; 2009 Dec; 22(6):544-52. PubMed ID: 19797947
[TBL] [Abstract][Full Text] [Related]
3. Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models.
Rivera-Hernandez T; Pandey M; Henningham A; Cole J; Choudhury B; Cork AJ; Gillen CM; Ghaffar KA; West NP; Silvestri G; Good MF; Moyle PM; Toth I; Nizet V; Batzloff MR; Walker MJ
mBio; 2016 Jun; 7(3):. PubMed ID: 27302756
[TBL] [Abstract][Full Text] [Related]
4. Current status of group A streptococcal vaccine development.
Dale JB
Adv Exp Med Biol; 2008; 609():53-63. PubMed ID: 18193657
[TBL] [Abstract][Full Text] [Related]
5. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
Good MF; Pandey M; Batzloff MR; Tyrrell GJ
Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.
Kotloff KL; Corretti M; Palmer K; Campbell JD; Reddish MA; Hu MC; Wasserman SS; Dale JB
JAMA; 2004 Aug; 292(6):709-15. PubMed ID: 15304468
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study.
Pastural É; McNeil SA; MacKinnon-Cameron D; Ye L; Langley JM; Stewart R; Martin LH; Hurley GJ; Salehi S; Penfound TA; Halperin S; Dale JB
Vaccine; 2020 Feb; 38(6):1384-1392. PubMed ID: 31843270
[TBL] [Abstract][Full Text] [Related]
8. Molecular biology of Group A
Brahmadathan NK
Indian J Med Microbiol; 2017; 35(2):176-183. PubMed ID: 28681803
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY
Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396
[TBL] [Abstract][Full Text] [Related]
10. Contribution of cryptic epitopes in designing a group A streptococcal vaccine.
Ozberk V; Pandey M; Good MF
Hum Vaccin Immunother; 2018; 14(8):2034-2052. PubMed ID: 29873591
[TBL] [Abstract][Full Text] [Related]
11. Group A streptococcus epidemiology and vaccine implications.
Cohen-Poradosu R; Kasper DL
Clin Infect Dis; 2007 Oct; 45(7):863-5. PubMed ID: 17806050
[No Abstract] [Full Text] [Related]
12. The quest for GAS vaccine.
Pandey M; Good MF
Oncotarget; 2015 Oct; 6(33):34063-4. PubMed ID: 26485764
[No Abstract] [Full Text] [Related]
13. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?
Smeesters PR; McMillan DJ; Sriprakash KS; Georgousakis MM
Expert Rev Vaccines; 2009 Dec; 8(12):1705-20. PubMed ID: 19905872
[TBL] [Abstract][Full Text] [Related]
14. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
[TBL] [Abstract][Full Text] [Related]
15. Lipid core peptide technology and group A streptococcal vaccine delivery.
Olive C; Batzloff MR; Toth I
Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
[TBL] [Abstract][Full Text] [Related]
16. Development of Group A streptococcal vaccines: an unmet global health need.
Sheel M; Moreland NJ; Fraser JD; Carapetis J
Expert Rev Vaccines; 2016; 15(2):227-38. PubMed ID: 26559880
[TBL] [Abstract][Full Text] [Related]
17. Group A
Young PG; Raynes JM; Loh JM; Proft T; Baker EN; Moreland NJ
Infect Immun; 2019 Jun; 87(6):. PubMed ID: 30936156
[TBL] [Abstract][Full Text] [Related]
18. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.
Tsoi SK; Smeesters PR; Frost HR; Licciardi P; Steer AC
J Immunol Res; 2015; 2015():167089. PubMed ID: 26101780
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial.
Pandey M; Powell J; Calcutt A; Zaman M; Phillips ZN; Ho MF; Batzloff MR; Good MF
Sci Rep; 2017 Oct; 7(1):13786. PubMed ID: 29062085
[TBL] [Abstract][Full Text] [Related]
20. Strategies in the development of vaccines to prevent infections with group A streptococcus.
Good MF; Batzloff MR; Pandey M
Hum Vaccin Immunother; 2013 Nov; 9(11):2393-7. PubMed ID: 23863455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]